This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.

Sue Desmond-Hellmann, MD, MPH, is a physician-scientist who led the development of the first gene-targeted drug for treating breast cancer.

  • Medical, scientific, and philanthropic career spanning 40 years: from academic medicine and clinical practice studying cancer and HIV/AIDS, to running research and product development at some of America’s top biotechnology companies, to leading higher education at one of California’s marquis graduate institutions, to running the world’s largest private foundation.
  • Former Chancellor of the University of California, San Francisco (2009-2014), and the first woman to hold the position.
  • At the leading biotech firm Genentech (1995-2009), led development of Herceptin® and served as Chief Medical Officer.
  • Member of U.S. National Academy of Medicine.
  • Co-chaired influential National Academies report that defined and charted the course of precision medicine.

Scroll to Top Scroll to Top
Top